Healthcare [ 4/11 ] | Drug Manufacturers—Specialty & Generic [ 29/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 23 | 0.11 Increased by +147.83% | -0.19 Increased by +831.02% |
| May 2, 23 | 0.11 Increased by +147.83% | -0.19 Increased by +831.02% |
| Mar 8, 23 | -0.23 Increased by +36.11% | -0.23 |
| Mar 7, 23 | -0.23 Increased by +28.13% | -0.23 |
| Nov 2, 22 | -0.23 Increased by +39.47% | -0.31 Increased by +83.25% |
| Nov 1, 22 | -0.23 Increased by +37.84% | -0.31 Increased by +83.25% |
| Aug 2, 22 | -0.36 Decreased by -9.09% | -0.36 |
| May 3, 22 | -0.32 Increased by +21.95% | -0.41 Increased by +53.54% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 11.13 M Decreased by -9.26% | 19.31 M Increased by +215.59% | Increased by +173.40% Increased by +227.38% |
| Dec 31, 22 | 10.68 M Decreased by -3.57% | -18.15 M Increased by +62.16% | Decreased by -169.90% Increased by +60.76% |
| Sep 30, 22 | 11.46 M Decreased by -13.73% | -16.22 M Decreased by -11.43% | Decreased by -141.49% Decreased by -29.16% |
| Jun 30, 22 | 13.27 M Decreased by -13.55% | -19.84 M Decreased by -60.44% | Decreased by -149.58% Decreased by -85.60% |
| Mar 31, 22 | 12.27 M Increased by +10.32% | -16.70 M Decreased by -13.84% | Decreased by -136.12% Decreased by -3.19% |
| Dec 31, 21 | 11.08 M Increased by +54.96% | -47.97 M Decreased by -135.49% | Decreased by -432.98% Decreased by -51.97% |
| Sep 30, 21 | 13.29 M Increased by +60.86% | -14.55 M Increased by +12.06% | Decreased by -109.54% Increased by +45.33% |
| Jun 30, 21 | 15.35 M Decreased by -29.20% | -12.37 M Decreased by -429.86% | Decreased by -80.59% Decreased by -648.44% |
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.